Literature DB >> 2392160

Antagonism of novel inotropic agents at A1 adenosine receptors and m-cholinoceptors in human myocardium.

M Ungerer1, M Böhm, R H Schwinger, E Erdmann.   

Abstract

The effects of the new inotropic agents saterinone, sulmazole, UD-CG 212.Cl and milrinone at A1 adenosine receptors and m-cholinoceptors were evaluated in human myocardium from patients with heart failure. At A1 adenosine receptors, all compounds inhibited 3H-DPCPX-binding to ventricular membrane preparations at micromolar concentrations. As judged from the K1-values, the rank order of potency was saterinone greater than sulmazole greater than UD-CG 212.Cl greater than milrinone. The new inotropic agents also displaced the binding of 3H-QNB at m-cholinoceptors. Except for saterinone, the concentration ranges of mean Ki-values were considerably higher at m-cholinoceptors than at A1 adenosine receptors. The rank order of potency was saterinone greater than sulmazole greater than UD-CG 212.Cl greater than milrinone. Competition of the A1 adenosine receptor agonist R-PIA to 3H-DPCPX-binding showed a biphasic curve with a shallow slope (Hill coefficient nH = 0.63) and revealed two affinity states of the A1 adenosine receptor. In the presence of guanine nucleotides [Gpp(NH)p], the competition curve showed one low affinity class of binding sites and was shifted to the right. In contrast, the competition curves of the new inotropic agents were characterized by a monophasic, steeper slope (mean Hill coefficient nH = 0.98). Guanine nucleotides had no effect. Similar results were obtained with saterinone and carbachol at m-cholinoceptors. Competition with carbachol revealed three affinity states of the m-cholinoceptor, the super-high affinity binding was reversed by Gpp(NH)p. Competition with saterinone revealed one class of binding sites which was not influenced by Gpp(NH)p.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2392160     DOI: 10.1007/bf00171739

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  37 in total

1.  Increase in calcium sensitivity of cardiac myofibrils contributes to the cardiotonic action of sulmazole.

Authors:  J C van Meel; R Zimmermann; W Diederen; E Erdman; U Mrwa
Journal:  Biochem Pharmacol       Date:  1988-01-15       Impact factor: 5.858

2.  Adenosine as inhibitor of myocardial effects of catecholamines.

Authors:  J Schrader; G Baumann; E Gerlach
Journal:  Pflugers Arch       Date:  1977-11-25       Impact factor: 3.657

3.  Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents.

Authors:  R E Weishaar; S D Burrows; D C Kobylarz; M M Quade; D B Evans
Journal:  Biochem Pharmacol       Date:  1986-03-01       Impact factor: 5.858

4.  Effects of several newer cardiotonic drugs on cardiac cyclic AMP metabolism.

Authors:  H S Ahn; D Eardley; R Watkins; N Prioli
Journal:  Biochem Pharmacol       Date:  1986-04-01       Impact factor: 5.858

5.  Relation of positive inotropic and chronotropic effects of pimobendan, UD-CG 212 Cl, milrinone and other phosphodiesterase inhibitors to phosphodiesterase III inhibition in guinea-pig heart.

Authors:  D Brunkhorst; H v der Leyen; W Meyer; R Nigbur; C Schmidt-Schumacher; H Scholz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-05       Impact factor: 3.000

6.  Adenosine inhibition of catecholamine-induced increase in force of contraction in guinea-pig atrial and ventricular heart preparations. Evidence against a cyclic AMP- and cyclic GMP-dependent effect.

Authors:  M Böhm; R Brückner; I Hackbarth; B Haubitz; R Linhart; W Meyer; B Schmidt; W Schmitz; H Scholz
Journal:  J Pharmacol Exp Ther       Date:  1984-08       Impact factor: 4.030

7.  Inhibition by adenosine of catecholamine-induced increase in rat atrial contractility.

Authors:  J B Rockoff; J G Dobson
Journal:  Am J Physiol       Date:  1980-09

8.  Modification by islet-activating protein of receptor-mediated regulation of cyclic AMP accumulation in isolated rat heart cells.

Authors:  O Hazeki; M Ui
Journal:  J Biol Chem       Date:  1981-03-25       Impact factor: 5.157

9.  Evidence against the adenosine-catecholamine antagonism under in vivo conditions.

Authors:  R Seitelberger; W Schütz; O Schlappack; G Raberger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-03       Impact factor: 3.000

10.  Modification by islet-activating protein of direct and indirect inhibitory actions of adenosine on rat atrial contraction in relation to cyclic nucleotide metabolism.

Authors:  M Endoh; M Maruyama; N Taira
Journal:  J Cardiovasc Pharmacol       Date:  1983 Jan-Feb       Impact factor: 3.105

View more
  3 in total

Review 1.  Drugs to facilitate recovery of neuromuscular blockade and muscle strength.

Authors:  Yuhji Saitoh
Journal:  J Anesth       Date:  2005       Impact factor: 2.078

Review 2.  Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.

Authors:  A Fitton; R N Brogden
Journal:  Drugs Aging       Date:  1994-05       Impact factor: 3.923

3.  EMD 53998 acts as Ca(2+)-sensitizer and phosphodiesterase III-inhibitor in human myocardium.

Authors:  R Uhlmann; R H Schwinger; I Lues; E Erdmann
Journal:  Basic Res Cardiol       Date:  1995 Sep-Oct       Impact factor: 17.165

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.